Day One Biopharmaceuticals (DAWN) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DAWN shares.
View DAWN analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 12-month price objectives for Day One Biopharmaceuticals' stock. Their DAWN share price forecasts range from $34.00 to $54.00. On average, they predict the company's share price to reach $42.14 in the next year. This suggests a possible upside of 215.0% from the stock's current price.
View analysts price targets for DAWN or view top-rated stocks among Wall Street analysts.

Day One Biopharmaceuticals' stock was trading at $21.52 at the beginning of 2023. Since then, DAWN stock has decreased by 37.8% and is now trading at $13.38.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our DAWN earnings forecast.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01.

ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

(DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Day One Biopharmaceuticals trades on the NASDAQ under the ticker symbol "DAWN."

Day One Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (8.98%), Franklin Resources Inc. (4.67%), BlackRock Inc. (4.10%), Braidwell LP (3.87%), State Street Corp (3.86%) and Goldman Sachs Group Inc. (2.75%). Insiders that own company stock include Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan.
View institutional ownership trends.

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DAWN stock can currently be purchased for approximately $13.38.

Day One Biopharmaceuticals (NASDAQ:DAWN) has a market capitalization of $1.16 billion. The company earns $-142,180,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

The company employs 124 workers across the globe.

Day One Biopharmaceuticals' mailing address is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is dayonebio.com. The company can be reached via phone at 650-484-0899 or via email at hans@lifesciadvisors.com.